These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 34365714)

  • 21. The prevalence of SARS-CoV-2 infection and the severity of the course of COVID-19 in patients with psoriasis treated with biologic therapy.
    Ciechanowicz P; Dopytalska K; Mikucka-Wituszyńska A; Dźwigała M; Wiszniewski K; Herniczek W; Szymańska E; Walecka I
    J Dermatolog Treat; 2022 May; 33(3):1581-1584. PubMed ID: 33317364
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety of SARS-CoV-2 vaccines in psoriatic patients treated with biologics: A real life experience.
    Musumeci ML; Caruso G; Trecarichi AC; Micali G
    Dermatol Ther; 2022 Jan; 35(1):e15177. PubMed ID: 34699117
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Compliance, safety concerns and anxiety in patients treated with biologics for psoriasis during the COVID-19 pandemic national lockdown: a multicenter study in the Czech Republic.
    Rob F; Hugo J; Tivadar S; Boháč P; Gkalpakiotis S; Vargová N; Arenbergerová M; Hercogová J
    J Eur Acad Dermatol Venereol; 2020 Nov; 34(11):e682-e684. PubMed ID: 32594549
    [No Abstract]   [Full Text] [Related]  

  • 24. Healthcare resource utilization and costs among patients with psoriasis treated with ixekizumab or adalimumab over 2 years of follow-up in real-world settings.
    Blauvelt A; Shi N; Murage MJ; Kern SA; Somani N; Burge R; Ridenour TL; Lew CR; Zimmerman NM; Zhu B
    J Med Econ; 2022; 25(1):741-749. PubMed ID: 35615978
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety of biologics for psoriasis patients during the COVID-19 pandemic: the experience from Wuhan, China.
    Zhao L; Du H; Alamgir M; Yang J; Miao X; Jiang B; Xia Y; Lou Y; Wang Y; Shen C; Zhu J; Chung WH; Li Y; Tao J
    Eur J Dermatol; 2020 Dec; 30(6):738-740. PubMed ID: 33459264
    [No Abstract]   [Full Text] [Related]  

  • 26. [BIOLOGICAL TREATMENT OF PSORIASIS IN TIME OF NEW CORONAVIRUS INFECTION COVID-19].
    Kruglova LS; Pereverzina NO; Rudneva NS; Kamynina NN; Oynotkinova OS
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2021 Aug; 29(Special Issue):1381-1387. PubMed ID: 34792893
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How does COVID-19 impact psoriasis practice, prescription patterns, and healthcare delivery for psoriasis patients? A cross-sectional survey study.
    El-Komy MHM; Abdelnaby A; El-Kalioby M
    J Cosmet Dermatol; 2021 Jun; 20(6):1573-1579. PubMed ID: 33811728
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of COVID-19 pandemic on psoriasis patients, and their immunosuppressive treatment: a cross-sectional multicenter study from Turkey.
    Kartal SP; Çelik G; Yılmaz O; Öksüm Solak E; Demirbağ Gül B; Üstünbaş TK; Gönülal M; Baysak S; Yüksel Eİ; Ünlü B; Güven M; Bozdağ A; Çınar G; Kartal S; Borlu M; Özden MG; Engin B; Serdaroğlu S; Balcı DD; Doğan B; Çiçek D; Yazıcı AC; Aytekin S; Şendur N; Sarıcaoglu H; Kaçar NG; Doğramacı AC; Dönmez L; Alpsoy E
    J Dermatolog Treat; 2022 Jun; 33(4):2137-2144. PubMed ID: 34030547
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence, risk and severity of SARS-CoV-2 infections in psoriasis patients receiving conventional systemic, biologic or topical treatment during the COVID-19 pandemic: a cross-sectional cohort study (PsoCOVID).
    Kwee KV; Murk JL; Yin Q; Visch MB; Davidson L; de Jong EMGJ; van den Reek JMPA; Tjioe M
    J Dermatolog Treat; 2023 Dec; 34(1):2161297. PubMed ID: 36545844
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Psoriasis-related treatment exposure and hospitalization or in-hospital mortality due to COVID-19 during the first and second wave of the pandemic: cohort study of 1 326 312 patients in France.
    Penso L; Dray-Spira R; Weill A; Zureik M; Sbidian E
    Br J Dermatol; 2022 Jan; 186(1):59-68. PubMed ID: 34310699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug Adherence and Persistence of Patients with Moderate to Severe Psoriasis Treated with Biologic Medications in a US Commercially Insured Population.
    Xu C; Teeple A; Wu B; Fitzgerald T; Feldman SR
    Dermatology; 2022; 238(3):438-447. PubMed ID: 34710876
    [TBL] [Abstract][Full Text] [Related]  

  • 33. COVID-19 risk and outcomes in adult asthmatic patients treated with biologics or systemic corticosteroids: Nationwide real-world evidence.
    Adir Y; Humbert M; Saliba W
    J Allergy Clin Immunol; 2021 Aug; 148(2):361-367.e13. PubMed ID: 34144110
    [TBL] [Abstract][Full Text] [Related]  

  • 34. National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments.
    Gelfand JM; Armstrong AW; Bell S; Anesi GL; Blauvelt A; Calabrese C; Dommasch ED; Feldman SR; Gladman D; Kircik L; Lebwohl M; Lo Re V; Martin G; Merola JF; Scher JU; Schwartzman S; Treat JR; Van Voorhees AS; Ellebrecht CT; Fenner J; Ocon A; Syed MN; Weinstein EJ; Gondo G; Heydon S; Koons S; Ritchlin CT
    J Am Acad Dermatol; 2021 May; 84(5):1254-1268. PubMed ID: 33422626
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Psoriasis and COVID-19: A narrative review with treatment considerations.
    Elmas ÖF; Demirbaş A; Kutlu Ö; Bağcıer F; Metin MS; Özyurt K; Akdeniz N; Atasoy M; Türsen Ü; Lotti T
    Dermatol Ther; 2020 Nov; 33(6):e13858. PubMed ID: 32686245
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adherence to systemic therapy in patients with psoriasis during the COVID-19 pandemic: A multicenter study.
    Oguz Topal I; Kara Polat A; Zindancı İ; Kıvanç Altunay İ; Akbulut TÖ; Arıkan EE; Topaloğlu Demir F; Sivaz O; Karadağ AS
    J Cosmet Dermatol; 2022 Jan; 21(1):39-47. PubMed ID: 34792848
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of COVID-19 vaccines in patients with psoriasis undergoing therapy with anti-interleukin agents.
    Talamonti M; Galluzzo M
    Expert Opin Biol Ther; 2021 Nov; 21(11):1535-1537. PubMed ID: 34357839
    [No Abstract]   [Full Text] [Related]  

  • 38. Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization and Mortality in Patients with Psoriasis: A Population-Based Study.
    Kridin K; Schonmann Y; Tzur Bitan D; Damiani G; Peretz A; Weinstein O; Cohen AD
    Am J Clin Dermatol; 2021 Sep; 22(5):709-718. PubMed ID: 34060006
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterizing patients with psoriasis on injectable biologics adalimumab, etanercept, and ustekinumab: A chart review study.
    Zhang M; Goren A; Lee S; DiBonaventura MD; Olson WH
    J Dermatolog Treat; 2016 Aug; 27(4):339-45. PubMed ID: 26558924
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Psoriasis healthcare during the COVID-19 pandemic: a survey among psoriasis patients (PsoCovidCare).
    Wortman CD; Godding LTH; Yin Q; Kwee KV; Visch MB; de Jong EMGJ; van den Reek JMPA; Tjioe M
    J Dermatolog Treat; 2024 Dec; 35(1):2369616. PubMed ID: 38897615
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.